BioInformant

Your Global Leader in Stem Cell Market Research

Home » mesenchymal stem cells » Page 5

Do You Know What Regions are Doing the Most Searches for Mesenchymal Stem Cells (MSCs)?

By Leave a Comment

Google Trends is a supplemental service of Google Incorporated that analyzes trend data collected through Google Search.

It shows how often a particular search term is entered relative to total search-volume across various regions of the world and in various languages.

It is an absolutely incredible market research tool for assessing stem cell market dynamics, because it reflects real-time social behavior related to specific stem cell types and provides public access to Google’s online search information. [Read more…]

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

By Leave a Comment

Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD).  This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”.  Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]

What Types of Mesenchymal Stem Cell (MSC) Research Are Getting Funded?

By Leave a Comment

To analyze trends within the mesenchymal stem cell (MSC) industry, it is valuable to consider grant rate data. Previously, the U.S. federal government operated an online tool called CRISP (“Computer Retrieval of Information on Scientific Projects”). It was a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other U.S. research institutions. The database allowed users to search the CRISP interface for grants funding for specific types of scientific research, using text-based search terms.

However, that has since been replaced by RePORTer (Research Portfolio Online Reporting Tools)1, a more powerful database and search tool supported by the U.S. Department of Health and Human Services. RePORTer allows users to search a comprehensive repository of National Institutes of Health (NIH) funded research projects resulting from NIH funding. [Read more…]

Current Bottlenecks in MSC Research: Widespread MSC Misconceptions

By Leave a Comment

This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.

We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation.  While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back.  [Read more…]

Cynata Therapeutics Enters Agreement for Strategic Alliance with Regience K.K. in Japan

By Leave a Comment

In recently released news, Cynata Therapeutics announced that it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and certain other Asian countries.

Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) derived from a one-time donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. This approach allows MSCs to be produced in nearly limitless quantities, eliminates product variability, and allows for lower manufacturing costs.

Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw.  To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]

BioInformant's World-Class Clients